Navigation Links
Yongye Biotechnology International Raises $9.4 Million in Private Placement
Date:9/10/2008

turing process is not expected to be completed until late summer of 2009.

"The money that we receive from this additional financing will help sustain our rapid pace of growth," said Mr. Wu, Chairman and CEO of Yongye. "Our business has outgrown our current manufacturing capabilities, and we need to be able to supply our distribution network with more of our current products and new products which we are planning to produce in the future."

The securities issued in the private placement have not been registered under the United States Securities Act of 1933 or the securities laws of any other jurisdiction. Accordingly, these securities may not be sold by investors in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the development, distribution and sales of fulvic acid based nutrients for plants and animals. The Company's patent pending processes and proprietary formulas allow it to create products which increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Forward Looking Statements

Certain statements set forth in this press release constitute "Forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecas
'/>"/>

SOURCE Yongye Biotechnology International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Yongye Biotechnology International Announces Second Quarter Results
2. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
3. Yongye Biotechnology International Retains CCG Investor Relations
4. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
5. Yongye Biotechnology Completes Reverse Merger and Completes $10.0 Million Private Financing
6. InNexus Biotechnology Strengthens Patent Team With New Leadership
7. InNexus Biotechnology CEO to Present at The Wall Street Analyst Forum in NYC
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. USDA Approves Syngenta and John Deere for Broadened Biotechnology Endorsement for Corn Crop Insurance
10. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... Antonio, TX (PRWEB) August 29, 2014 ... and ISO 13485:2003 certified, GAMP® 5 compliant imaging ... awarded an international Phase II clinical trial to ... lymphoma. , Throughout this trial, Intrinsic Imaging will ... not limited to, protocol and charter development, site ...
(Date:8/28/2014)... LAFAYETTE, Ind. A new research platform ... properties of tiny structures undergoing stress and ... to improve designs for microelectronics and batteries., ... reveals information about how heating and the ... mechanical properties. Researchers have discussed the merits ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... 10 Corthera Inc. today,announced that an interim ... portion of a Phase II/III multicenter, randomized, double-blind,international ... the,company,s investigational drug for treatment of acute heart ... presented by John R. Teerlink, M.D.,Professor of Medicine, ...
... 3SBio Inc. (Nasdaq:,SSRX), a leading biotechnology company focused ... in China,today announced that it has filed with ... approval of NuLeusin for the treatment of late,stage ... expected to,be the only treatment of this kind ...
... today,announced financial results for the second quarter ended September ... quarter, representing an,increase of 27.1% from 100.9 billion yen ... results of PENTAX included in the scope of,consolidation during ... billion yen, a 23.2% decrease compared with,26.8 billion yen ...
Cached Biology Technology:Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure 2Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Corthera's Relaxin in Acute Heart Failure 33SBio Inc. Files for SFDA Approval of NuLeusin 23SBio Inc. Files for SFDA Approval of NuLeusin 33SBio Inc. Files for SFDA Approval of NuLeusin 4Hoya Announces Second Quarter and First Half Financial Results for FY2008 2
(Date:9/1/2014)... the Nomenclature Section of the XVIII International Botanical Congress ... meeting is held every six years and it is ... naming algae, fungi and plants get together to debate ... they study. This is the primary product of the ... and plants, which was published in 2012. The other ...
(Date:8/31/2014)... go after each other. But when viruses invade bacteria, ... Sometimes viruses actually carry helpful genes that a bacterium ... attack its own hosts. , Scientists have assumed the ... anything it recognized as invading viral genes. However, new ... variety of the bacterial immune system known as the ...
(Date:8/29/2014)... at UC Davis have made some surprising discoveries ... Studying simian immunodeficiency virus (SIV), the team found ... cells are early responders to viral invasion and ... a cytokine called interleukin-1 beta (IL-1β). , ... causes breakdown of the gut epithelium that provides ...
Breaking Biology News(10 mins):Week-long meeting on naming algae, fungi, and plants recorded for posterity 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3The early cost of HIV 2
... -- Zeroing in on the early cell mutations that enable a ... a personalized therapy to stop it. Scientists were able to use ... order in which these abnormalities form to analyze the pattern of ... findings, which are published in the July edition of Cancer ...
... 29, 2011 BD Biosciences, a segment of ... availability of BD Recharge™, a chemically defined (CD) ... offers productivity comparable to yeast-based peptones. ... for biopharmaceutical cell culture," said Robert Hallenbeck, Vice ...
... uncovered half-a-billion-year-old fossils demonstrating that primitive animals had excellent vision. ... South Australian Museum and the University of Adelaide ... from a recently swatted fly. This discovery will be ... Nature . The lead author is ...
Cached Biology News:Scientists develop method to determine order of mutations that lead to cancer 2BD Biosciences Introduces Chemically Defined Cell Culture Media Supplement that Increases Biopharmaceutical Protein Production 2New fossils demonstrate that powerful eyes evolved in a twinkling 2
... The EZ DNA Methylation Kit uses a ... for DNA methylation analysis. The kit is ... takes place between cytosine and sodium bisulfite ... EZ DNA Methylation Kits innovative in-column desulphonation ...
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... EIA Principle: The ... LTE4 are products of arachidonic ... glutathione-S-transferase. In the past, they ... Substances of Anaphylaxis (SRS-A)". They ...
Biology Products: